Oligonucleotides, Antisense

"Oligonucleotides, Antisense" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize.

Descriptor ID	D016376
MeSH Number(s)	D13.150.480 D13.444.600.150.640 D13.695.578.424.480 D27.720.470.530.600.150.640
Concept/Terms	Oligonucleotides, Antisense Oligonucleotides, Antisense Antisense Oligonucleotides Anti-Sense Oligonucleotides Anti Sense Oligonucleotides Oligonucleotides, Anti-Sense

Below are MeSH descriptors whose meaning is more general than "Oligonucleotides, Antisense".

Chemicals and Drugs [D]
Nucleic Acids, Nucleotides, and Nucleosides [D13]
Antisense Elements (Genetics) [D13.150]
Oligonucleotides, Antisense [D13.150.480]
Nucleic Acids [D13.444]
Nucleic Acid Probes [D13.444.600]
Antisense Elements (Genetics) [D13.444.600.150]
Oligonucleotides, Antisense [D13.444.600.150.640]
Nucleotides [D13.695]
Polynucleotides [D13.695.578]
Oligonucleotides [D13.695.578.424]
Oligonucleotides, Antisense [D13.695.578.424.480]
Chemical Actions and Uses [D27]
Specialty Uses of Chemicals [D27.720]
Laboratory Chemicals [D27.720.470]
Molecular Probes [D27.720.470.530]
Nucleic Acid Probes [D27.720.470.530.600]
Antisense Elements (Genetics) [D27.720.470.530.600.150]
Oligonucleotides, Antisense [D27.720.470.530.600.150.640]

Below are MeSH descriptors whose meaning is related to "Oligonucleotides, Antisense".

Below are MeSH descriptors whose meaning is more specific than "Oligonucleotides, Antisense".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Oligonucleotides, Antisense" by people in this website by year, and whether "Oligonucleotides, Antisense" was a major or minor topic of these publications.

Bar chart showing 97 publications over 27 distinct years, with a maximum of 9 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	3	0	3
1998	0	2	2
1999	0	1	1
2001	1	1	2
2002	3	2	5
2003	2	3	5
2004	0	2	2
2005	2	5	7
2006	1	3	4
2007	1	0	1
2008	1	2	3
2009	1	0	1
2010	1	1	2
2011	3	1	4
2012	1	2	3
2014	1	2	3
2015	1	2	3
2016	3	2	5
2017	1	1	2
2018	6	2	8
2019	1	2	3
2021	6	0	6
2022	6	3	9
2023	1	2	3
2024	3	1	4
2025	3	1	4
2026	1	1	2

Below are the most recent publications written about "Oligonucleotides, Antisense" by people in Profiles.

Blitek M, Le Coz O, Ogor V, Fakih HH, Khvorova A, Goyenvalle A. Efficient Downregulation of Flt-1 Mediated by Splice Switching ASO in Murine Endothelial Cells. Nucleic Acid Ther. 2026 Jun; 36(3):147-157.

View in: PubMed
Agrawal S. Transient Cyclic Structured Oligonucleotide Designs for Therapeutic Applications. Curr Protoc. 2026 Feb; 6(2):e70319.

View in: PubMed
Groenwold ET, Montulet A, Stan T, van de Vijver D, McCorquodale D, McHugh N, Echeverria D, Winter CT, van de Wal M, O'Reilly D, Khvorova A, Aartsma-Rus A, Damha MJ. Conjugated Antisense Oligonucleotides for Skipping of Duchenne Muscular Dystrophy Exon 53: A Cautionary Study. Nucleic Acid Ther. 2026 Apr; 36(2):100-108.

View in: PubMed
Shneider NA, Harms MB, Korobeynikov VA, Rifai OM, Hoover BN, Harrington EA, Aziz-Zaman S, Singleton J, Jamil A, Madan VR, Lee I, Andrews JA, Smiley RM, Alam MM, Black LE, Shin M, Watts JK, Walk D, Newman D, Pascuzzi RM, Weber M, Neuwirth C, Da Cruz S, Soriano A, Lane R, Henry S, Mathews J, Jafar-Nejad P, Norris D, Rigo F, Brown RH, Miller S, Crean R, Bennett CF. Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series. Lancet. 2025 Jun 07; 405(10494):2075-2086.

View in: PubMed
Belgrad J, McConnell E, Leonard S, Nolen N, Lauffer MC, Watts JK, Yu T, Yan WX, Aartsma-Rus A. The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing. Nucleic Acids Res. 2025 Apr 22; 53(8).

View in: PubMed
Jung S, Richter JD. Trinucleotide repeat expansion and RNA dysregulation in fragile X syndrome: emerging therapeutic approaches. RNA. 2025 02 19; 31(3):307-313.

View in: PubMed
Moazami MP, Rembetsy-Brown JM, Sarli SL, McEachern HR, Wang F, Ohara M, Wagh A, Kelly K, Krishnamurthy PM, Weiss A, Marosfoi M, King RM, Motwani M, Gray-Edwards H, Fitzgerald KA, Brown RH, Watts JK. Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system. Mol Ther. 2024 Dec 04; 32(12):4401-4417.

View in: PubMed
Susorov D, Echeverria D, Khvorova A, Korostelev AA. mRNA-specific readthrough of nonsense codons by antisense oligonucleotides (R-ASOs). Nucleic Acids Res. 2024 08 27; 52(15):8687-8701.

View in: PubMed
Sarli SL, Fakih HH, Kelly K, Devi G, Rembetsy-Brown JM, McEachern HR, Ferguson CM, Echeverria D, Lee J, Sousa J, Sleiman HF, Khvorova A, Watts JK. Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo. Nucleic Acids Res. 2024 05 22; 52(9):4799-4817.

View in: PubMed
Sharma VK, Mangla P, Singh SK, Prasad AK. Triazole-linked Nucleic Acids: Synthesis, Therapeutics and Synthetic Biology Applications. Curr Org Synth. 2024; 21(4):436-455.

View in: PubMed

People

Explore

Similar Concepts

Top Journals